1588 studies found for:    melanoma
Show Display Options
Rank Status Study
21 Completed
Has Results
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain
Condition: Melanoma and Brain Metastases
Intervention: Drug: GSK2118436
22 Terminated
Has Results
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
Conditions: Metastatic Melanoma;   Metastatic Renal Cancer
Interventions: Drug: Zanolimumab;   Drug: Aldesleukin
23 Unknown  A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma
Conditions: Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma
Intervention: Biological: CB-10-01 (Transgenic Lymphocyte Immunization)
24 Completed Study of Circulating Tumor Cells Before and After Treatment in Patients With Metastatic Melanoma
Condition: Melanoma
Intervention: Other: Sampling of blood
25 Recruiting CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Metastatic Carcinoma of Unknown Primary;   Metastatic Intraocular Melanoma;   Mucosal Melanoma;   Stage IIB Intraocular Melanoma;   Stage IIB Melanoma;   Stage IIC Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIA Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIB Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IIIC Melanoma;   Stage IV Intraocular Melanoma;   Stage IV Melanoma
Interventions: Biological: recombinant flt3 ligand;   Biological: DEC-205/NY-ESO-1 fusion protein CDX-1401;   Biological: neoantigen-based melanoma-poly-ICLC vaccine;   Other: laboratory biomarker analysis;   Other: pharmacological study
26 Active, not recruiting Pilot Study of Infrared Imaging of Cutaneous Melanoma
Condition: Melanoma
Intervention:
27 Recruiting A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma
Condition: High Risk Melanoma
Interventions: Drug: Ipilumimab;   Radiation: Radiation
28 Unknown  Vaccine Therapy in Treating Patients With Metastatic Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: QS21;   Biological: incomplete Freund's adjuvant;   Biological: peptide 946 melanoma vaccine;   Biological: peptide 946-tetanus peptide conjugate melanoma vaccine;   Biological: tetanus peptide melanoma vaccine
29 Terminated Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma
Condition: Melanoma
Intervention: Biological: A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1
30 Completed Evaluation of a Simulation Training Tool to Identify Lesions Requiring Further Screening for Melanoma
Conditions: Skin Simulation Model;   Mastery Learning Model to Simulation Training for Visual Screening for Melanoma and Skin Biopsy
Intervention: Other: Simulation teaching session
31 Unknown  Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma
Conditions: Advanced Melanoma;   Untreated Patients
Interventions: Drug: dacarbazine plus Endostar (Experimental group);   Drug: dacarbazine plus placebo (control group)
32 Recruiting Adoptive T Cell Therapy for Metastatic Ocular Melanoma
Conditions: Metastatic Ocular Melanoma;   Metastatic Uveal Melanoma
Interventions: Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Tumor Infiltrating Lymphocytes
33 Completed Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells
Conditions: Metastatic Melanoma;   Absence of CNS Metastases
Intervention: Biological: Proteasome siRNA and tumor antigen RNA-transfected dendritic cells
34 Completed Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
Condition: Melanoma
Interventions: Biological: Autologous, DNP-modified vaccine (M-Vax);   Biological: Autologous, DNP-Modified Melanoma Vaccine;   Biological: Autologous, DNP-Modified Vaccine
35 Recruiting Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma
Condition: Metastatic Melanoma
Intervention: Radiation: WBRT
36 Recruiting Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma
Conditions: Hereditary Multiple Melanoma;   Melanoma (Skin)
Interventions: Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: molecular genetic technique;   Genetic: mutation analysis;   Other: laboratory biomarker analysis;   Procedure: mutation carrier screening;   Procedure: study of high risk factors
37 Not yet recruiting Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
Conditions: High Risk HLA-A2+ Melanoma;   Metastatic Disease
Intervention: Biological: Melanoma vaccine modified to express HLA A2/4-1BB ligand
38 Recruiting Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma
Condition: Melanoma (Skin)
Interventions: Genetic: gene expression analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry;   Other: medical chart review
39 Terminated Study for the Evaluation Dabrafenib (Tafinlar) and Trametinib (Mekinist) Plus DNE3 in Patients With Metastatic Melanoma
Conditions: Melanoma;   Metastatic Melanoma
Interventions: Drug: Dabrafenib;   Drug: Trametinib;   Biological: DNE3
40 Suspended Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma
Condition: Melanoma
Interventions: Biological: MELITAC 12.1;   Drug: Imiquimod

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years